4例患者使用注射用甘露聚糖肽后, 出现呼吸困难等症状, 立即停用注射用甘露聚糖肽, 并采用相关对症处理后, 患者呼吸困难缓解, 呼吸基本恢复正常.上述患者注射用甘露聚糖肽的使用与呼吸困难的发生有合理的时间顺序, 停用该药后症状均消失, 特别是其中1例患者再次使用注射用甘露聚糖肽时, 再次出现上述症状.故可判断该不良反应由注射用甘露聚糖肽所致.甘露聚糖肽属于大分子糖肽类药物, 可作为抗原进入体内, 诱发过敏.故临床使用该药时应严格按照药品说明书推荐剂量使用, 药液配置不宜过浓, 滴注速度不易过快, 并密切监测, 一旦发生呼吸困难等不良反应, 立即停药并对症处理.%Four patients showed dyspnea and other symptoms after using manngan peptide for injection, and then stopped using manngan peptide for injection immediately. After symptomatic treatment, the patients' dyspnea was relieved and the breathing was basically restored to the normal state. There was a reasonable chronological sequence between the use of manngan peptide for injection and the occurrence of dyspnea in the four patients, and the symptoms disappeared after withdraw of the drugs, in particular, when one of the patients used the mannan peptide for injection again, the above symptoms reappeared. Therefore, it can be concluded that the adverse drug reactions were caused by manngan peptide for injection. Mannan peptide is macromolecular glycopeptide drugs that can enter the body as antigens and induce allergies. Therefore, the drug should be used strictly in accordance with the recommended dosage in the drug instructions in clinical use, the liquid configuration should not be too thick, the infusion speed should not be too fast, and closely monitored is necessary, in cases of adverse drug reactions such as dyspnea, the drugs should be stopped immediately and symptomatic treatment should be carried out.
展开▼
